Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Persistent enlarged lymph glands in the neck may indicate cancer

Referring patients with unexplained swollen neck glands for specialist investigations could help to avoid some of the thousands of deaths each year from lymphoma, a type of cancer.

27 Apr 2015

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Results announced today at The International Liver Congress 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer.

25 Apr 2015

Global changes in cancer cells' epigenome may determine disease progression

Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings from Weill Cornell Medical College investigators indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin Lymphoma.

21 Apr 2015

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

The "Radiation and the Modern Management of Lymphoma" issue (May 1, 2015) of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology, is focused on the integral role of radiation therapy in current lymphoma treatment.

17 Apr 2015

Changes in JAK/STAT3 cell signaling pathway drive ALK-negative ALCL

The first-ever systematic study of the genomes of patients with ALK-negative anaplastic large cell lymphoma (ALCL), a particularly aggressive form of non-Hodgkin's lymphoma, shows that many cases of the disease are driven by alterations in the JAK/STAT3 cell signaling pathway.

15 Apr 2015

Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita, the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate.

1 Apr 2015

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials testing an experimental treatment in which patients' own immune cells are genetically engineered to fight their cancer.

30 Mar 2015

New immunotoxin found to be safe, effective in patients with B-cell malignancies

Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained.

13 Mar 2015

Breakthrough therapies for blood cancers may provide reasonable value for money spent

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent.

6 Feb 2015

Breakthrough blood cancer therapies may provide reasonable value for money spent

6 Feb 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

TUM researchers discover new mechanism for regulating programmed cell death

Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. Now, researchers at Technische Universität München have discovered a previously unknown mechanism for regulating programmed cell death.

18 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno's collaboration partner, Memorial Sloane Kettering Cancer Center.

18 Nov 2014

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Newly-identified cancer cell fingerprints in the blood could one day help doctors diagnose a range of children's cancers faster and more accurately, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference next week.

3 Nov 2014

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets.

31 Oct 2014